Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Denmark
  4. Nasdaq Copenhagen
  5. ViroGates A/S
  6. News
  7. Summary
    VIRO   DK0061030574

VIROGATES A/S

(VIRO)
SummaryQuotesChartsNewsCalendarCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Invitation to ViroGates' Q3 2021 presentation

11/10/2021 | 02:46am EST

ViroGates A/S will publish its Interim Report for Q3 2021 on Thursday 11 November 2021.

The following Monday, 15 November 2021 at 11.00 CET, the company will join a web conference hosted by Västra Hamnen Corporate Finance to present a summary of the report. The company will be represented by CEO Jakob Knudsen and CFO Mark Christian Hvidberg da Silva. After their presentation, there will be a Q&A session. The conference will be held in English. You can join the conference by computer or mobile devices.

The number of participants is limited and we recommend signing up early in order to secure a spot. Please register via the following link:

https://attendee.gotowebinar.com/register/8438786246686366733

A recording of the web conference will afterwards be made available via ViroGates’ homepage www.virogates.com and Västra Hamnen Corporate Finance’s YouTube channel.

© Modular Finance, source Nordic Press Releases

All news about VIROGATES A/S
01/11NATURE MEDICINE PUBLICATION : Early anakinra treatment for COVID-19 guided by suPAR saves ..
PU
2021ViroGates publishes the financial calendar for 2022
AQ
2021ViroGates on positive EMA opinion regarding suPAR-guided anakinra treatment (Video)
AQ
2021ViroGates announces a positive opinion from the CHMP of the EMA for suPAR-guided anakin..
AQ
2021ViroGates Announces Positive Opinion from the CHMP of the EMA for suPAR-Guided Anakinra..
CI
2021VIROGATES A/S : SuPAR independently predicts severity and length of hospitalisation in pat..
PU
2021ViroGates announces a development, supply and collaboration agreement with Italy-based ..
AQ
2021FRONTIERS IN IMMUNOLOGY PUBLICATION : Soluble Urokinase Plasminogen Activator Receptor (su..
PU
2021ViroGates awarded a 2.8 DKKm Innobooster grant by The Innovation Fund Denmark to finali..
AQ
2021NATURE MEDICINE PUBLICATION : Early anakinra treatment for COVID-19 guided by suPAR saves ..
PU
More news
Financials
Sales 2020 5,35 M 0,82 M 0,82 M
Net income 2020 -18,7 M -2,87 M -2,87 M
Net cash 2020 33,5 M 5,13 M 5,13 M
P/E ratio 2020 -13,4x
Yield 2020 -
Capitalization 507 M 77,7 M 77,6 M
EV / Sales 2019 17,5x
EV / Sales 2020 41,3x
Nbr of Employees 14
Free-Float -
Chart VIROGATES A/S
Duration : Period :
ViroGates A/S Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends VIROGATES A/S
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Managers and Directors
Jakob Knudsen Chief Executive Officer
Mark Christian Hvidberg da Silva Chief Financial Officer
Lars Kongsbak Chairman
Jesper Eugen-Olsen Chief Scientific Officer
J÷rgen Axel Thorball Director
Sector and Competitors
1st jan.Capi. (M$)
VIROGATES A/S11.11%78
EXACT SCIENCES CORPORATION0.77%13 515
GUARDANT HEALTH, INC.-22.44%7 886
BGI GENOMICS CO., LTD.11.15%6 529
ADAPTIVE BIOTECHNOLOGIES CORPORATION-31.04%2 731
INVITAE CORPORATION-23.12%2 658